Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9744375 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL4328796 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL647264 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL9744380 | 1.00 | TSHR (0.37) | TSHRBTKGAAEPHX1CTSS | |
| Hydrochloric Acid SCHEMBL30546580 | 0.98 | TSHR (0.36) | TSHRBTKGAAEPHX1CTSS | |
| SCHEMBL5131640 | 0.98 | BTK (0.36) | TSHRBTKGAAKMT2A | |
| SCHEMBL4996407 | 0.98 | BTK (0.36) | TSHRBTKGAAKMT2A | |
| SCHEMBL3672475 | 0.97 | BTK (0.36) | TSHRBTKKMT2A | |
| SCHEMBL2350718 | 0.92 | KMT2A (0.34) | BTKGAAKMT2A | |
| SCHEMBL2350728 | 0.92 | KMT2A (0.34) | BTKGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2863905-A2 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2015-04-29 | — | — | EP | disclosed |
| WO-2013192046-A2 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-12-27 | — | — | WO | disclosed |
| EP-2635556-A2 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061418-A2 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-7265220-B2 | Amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | LES LABORATORIES SERVIER (FR) | 2007-09-04 | — | — | US | disclosed |
| US-20050085517-A1 | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | LES LABORATOIRES SERVIER (FR) | 2005-04-21 | — | — | US | disclosed |
| EP-1476421-A2 | NOVEL AMINO ACID DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID DERIVATIVE | LES LABORATOIRES SERVIER (FR) | 2004-11-17 | — | — | EP | disclosed |
| US-6632921-B1 | Administering as topical fungicide against Candida | G. D SEARLE & CO | 2003-10-14 | — | — | US | disclosed |
| WO-2003070690-A2 | NOVEL AMINO ACID DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID DERIVATIVE | LES LABORATOIRES SERVIER (FR) | 2003-08-28 | — | — | WO | disclosed |
| EP-1135023-A4 | AMINOBENZISOXAZOLE COMPOUNDS AND LIBRARIES THEREOF | LILLY CO ELI (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1135023-A1 | AMINOBENZISOXAZOLE COMPOUNDS AND LIBRARIES THEREOF | ELI LILLY AND COMPANY (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000027199-A1 | AMINOBENZISOXAZOLE COMPOUNDS AND LIBRARIES THEREOF | ELI LILLY AND COMPANY (US) | 2000-05-18 | — | — | WO | disclosed |
| US-5942600-A | COMPOUNDS WITH SELECTIVE CONTROL OF FUNGAL ORGANISM CANDIDA ALBICANS FOR TREATMENT IN HUMANS, FOR EXAMPLE THOSE WITH WEAKENED IMMUNE SYSTEMS DUE TO AIDS; SPECIES-SPECIFIC CONTROL | G. D. SEARLE & CO. (US) | 1999-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085517-A1 | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | ARGLU1, PNISR, ATIC | TSHR 139/4885BTK 1903/4885GAA 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.